Mimetogen Pharmaceuticals has begun enrolling patients in a pivotal phase 3 clinical study of an ophthalmic solution for the treatment of dry eye syndrome, according to a press release.
MIM-D3 ophthalmic solution is the first in a class of molecules called TrkA agonists, the release said. It stimulates the production of mucin, which plays a role in the protection and health of the ocular surface, and it may have further benefits, such as improving neural function, which may improve corneal sensitivity and integrity.
The trial will evaluate the safety and efficacy of MIM-D3 in the treatment of dry eye syndrome. Approximately 400 patients will be randomized to receive 1% MIM-D3 ophthalmic solution or placebo twice daily over an 8-week period, according to the release. The primary endpoints are corneal fluorescein staining score and ocular dryness; safety and comfort also will be evaluated.
Bausch + Lomb has an option to license MIM-D3 for dry eye and may choose to pursue development based on the phase 3 study results.